All In Biotech

Drug Trial Radar · NCT04638829

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Mar 15, 2021

Primary completion

Jan 3, 2024

Study completion Jan 3, 2024

Sponsor

Lead sponsor
Sobi, Inc.Industry
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

Conditions

  • Immune Thrombocytopenia

Interventions

  • Avatrombopag Oral TabletDrug

    Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability (Adverse Events)Time frame: Screening through Day 90 or End of Study

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Sobi Site 110

    Tucson, Arizona

  • Sobi Site 119

    Whittier, California

  • Sobi Site 123

    Washington D.C., District of Columbia

  • Sobi Site 129

    Miami, Florida

  • Sobi Site 120

    Ocala, Florida

  • Sobi Site 125

    St. Petersburg, Florida

  • Sobi Site 118

    Tampa, Florida

  • Sobi Site 126

    Chicago, Illinois

  • Sobi Site 109

    Peoria, Illinois

  • Sobi Site 124

    New Orleans, Louisiana

  • Sobi Site 101

    Bethesda, Maryland

  • Sobi Site 103

    Lincoln, Nebraska

  • Sobi Site 121

    Chapel Hill, North Carolina

  • Sobi Site 116

    Greenville, North Carolina

  • Sobi Site 128

    Cleveland, Ohio

  • Sobi Site 127

    Philadelphia, Pennsylvania

  • Sobi Site 102

    York, Pennsylvania

  • Sobi Site 104

    Rock Hill, South Carolina

  • Sobi Site 113

    Dallas, Texas

  • Sobi Site 108

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.